Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-16-008009
Filing Date
2016-08-15
Accepted
2016-08-15 16:35:49
Documents
54
Period of Report
2016-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q syrs-20160630x10q.htm 10-Q 1646946
2 EX-31.1 syrs-20160630ex311b988b0.htm EX-31.1 11069
3 EX-31.2 syrs-20160630ex312d9f27e.htm EX-31.2 11501
4 EX-32.1 syrs-20160630ex321e3d36f.htm EX-32.1 7429
5 EX-32.2 syrs-20160630ex3226e4fee.htm EX-32.2 7555
  Complete submission text file 0001558370-16-008009.txt   4822761

Data Files

Seq Description Document Type Size
6 EX-101.INS syrs-20160630.xml EX-101.INS 765070
7 EX-101.SCH syrs-20160630.xsd EX-101.SCH 31867
8 EX-101.CAL syrs-20160630_cal.xml EX-101.CAL 28495
9 EX-101.DEF syrs-20160630_def.xml EX-101.DEF 157166
10 EX-101.LAB syrs-20160630_lab.xml EX-101.LAB 343867
11 EX-101.PRE syrs-20160630_pre.xml EX-101.PRE 259126
Mailing Address 480 ARSENAL STREET SUITE 130 WATERTOWN MA 02472
Business Address 480 ARSENAL STREET SUITE 130 WATERTOWN MA 02472 617-744-1340
Syros Pharmaceuticals, Inc. (Filer) CIK: 0001556263 (see all company filings)

EIN.: 453772460 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37813 | Film No.: 161833288
SIC: 2834 Pharmaceutical Preparations